Type of publication:
Conference abstract
Author(s):
*Mehra S.
Citation:
British Journal of Dermatology. Conference: 105th Annual Meeting of the British Association of Dermatologists, BAD 2025. Glasgow United Kingdom. 193(Supplement 1) (pp i34), 2025. Date of Publication: 01 Jul 2025.
Abstract:
The aim of this study was to evaluate the efficacy and safety of injectable bio-revitalizers and rejuvenative therapies licensed under Medicines and Healthcare products Regulatory Agency (MHRA) and National Institute for Health and Care Excellence (NICE) guidelines. These included platelet-rich plasma (PRP) and exosome-based treatments. This review synthesizes clinical outcomes, safety profiles and patient-reported satisfaction to provide evidence-based recommendations for advancing dermatological practice in the UK. A systematic review was conducted following the PRISMA guidelines. Databases including PubMed, MEDLINE, Embase and Cochrane Library were searched for studies published between 2010 and 2023. Keywords included 'injectable bio-revitalisers', 'hyaluronic acid', 'polynucleotides', 'platelet-rich plasma', 'exosome therapy', 'efficacy' and 'safety'. Inclusion criteria focused on licensed products approved in the UK under MHRA and NICE regulations, such as Profhilo, Restylane Skinboosters, Sunekos, Nucleofill, Juvelook, PRP and exosomebased therapies. Data extraction covered clinical efficacy (e.g. hydration, elasticity, wrinkle reduction), safety (e.g. adverse events, tolerability) and patient-reported outcomes. Twenty-six studies involving 2450 patients were included. Key findings highlighted consistent efficacy and safety across therapies. Hyaluronic acid-based bio-revitalizers (e.g. Profhilo, Restylane Skinboosters) improved hydration (20-25%), elasticity (15-18%) and wrinkle reduction, with patient satisfaction rates of 88-90%. Adverse events were limited to transient erythema and swelling. Polynucleotidebased therapies (e.g. Nucleofill, Juvelook) enhanced skin regeneration, provided antioxidant benefits and showed sustained results up to 6 months, with minimal adverse effects and improved firmness (18-22%). PRP showed moderate-to-significant improvements in skin texture and fine lines, with 76% of patients reporting enhanced skin quality. Adverse events were mild. Exosome-based therapies had emerging evidence indicating improvements in tone, texture and collagen stimulation, with high satisfaction rates (89%) and minimal adverse events. In conclusion, injectable bio-revitalizers, including PRP and exosome-based therapies, demonstrate high efficacy and safety profiles when adhering to MHRA and NICE guidelines. These therapies provide innovative, minimally invasive options for skin rejuvenation, with consistent patient satisfaction. Standardized treatment protocols, tailored patient selection criteria, and long-term studies are needed to optimize outcomes. PRP and exosome-based therapies expand regenerative dermatology and enhance patient care. Recommendations for practice are as follows: (i) incorporate PRP and exosome therapies into bio-revitalization strategies, emphasizing regenerative potential; (ii) develop national guidelines for standardized protocols; (iii) establish multicentre registries for tracking long-term outcomes and (iv) implement training programmes on appropriate use and safety considerations. This review offers a comprehensive evaluation of licensed bio-revitalizers and rejuvenate therapies, providing colleagues with evidence-based insights for improving patient care and advancing practice in aesthetic and therapeutic dermatology. The findings serve as a valuable teaching tool, fostering reflection on current practices and encouraging innovation within the field.
DOI: 10.1093/bjd/ljaf085.065
Link to full-text [no password required]
